{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.61","value":"138.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"}],"units":"Participants"}],"title":"Systolic Blood Pressure: Baseline (actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.15","value":"136.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Systolic Blood Pressure: Post-dosing (actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.24","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Systolic Blood Pressure: Change from Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.18","value":"78.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"}],"units":"Participants"}],"title":"Diastolic Blood Pressure: Baseline (actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.57","value":"77.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Diastolic Blood Pressure: Post-dosing (actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.20","value":"-1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Diastolic Blood Pressure: Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"}],"units":"Participants"}],"description":"The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with suspected recurrence of prostate cancer and negative or equivocal findings per institutional standard of care conventional imaging were enrolled to receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL injection followed by a single PET/CT scan acquired 1 to 2 hours post-dosing.","id":"OG000","title":"18F-DCFPyL Injection"}],"paramType":"MEAN","populationDescription":"The Safety Set includes all participants who received any amount of 18F-DECPyL.","reportingStatus":"POSTED","timeFrame":"Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.","title":"The Change From Pre- to Post- 18F-DCFPyl Dosing in Blood Pressure (Safety Outcome Measure)","type":"SECONDARY","unitOfMeasure":"mmHg"}